Search
3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole
go.drugbank.com/drugs/DB08727ExperimentalThis compound belongs to the phenol ethers. … These are aromatic compounds containing an ether group substituted with a benzene ring. 3-Methyl-5-(7-{4-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]phenoxy}heptyl)-1,2-oxazole is known to target genome
Gam-COVID-Vac
go.drugbank.com/drugs/DB15848InvestigationalPreliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a good safety profile in both trials. … The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV
XEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
Freneslerbart
go.drugbank.com/drugs/DB19080InvestigationalFreneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic
TMC-649128
go.drugbank.com/drugs/DB15152InvestigationalTMC-649128 is under investigation in clinical trial NCT01391117 (TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics
Oxibendazole
go.drugbank.com/drugs/DB04910ExperimentalVet approvedOxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.
Darusentan
go.drugbank.com/drugs/DB04883InvestigationalDarusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
Rusalatide
go.drugbank.com/drugs/DB05309InvestigationalTP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.
Elesclomol
go.drugbank.com/drugs/DB05719InvestigationalIn preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal
Ceperognastat
go.drugbank.com/drugs/DB21591InvestigationalCeperognastat is under investigation in clinical trial NCT05063539 (A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease).